3-(3,4-dichlorophenoxy)propan-1-amine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(3,4-dichlorophenoxy)propan-1-amine
• 英文别名: 3-(3,4-Dichloro-phenoxy)-propylamine
• 化学式: C₉H₁₁Cl₂NO
• 分子量: 220.098
• InChiKey: JZFORTINBLQENE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(3,4-dichlorophenoxy)propan-1-amine 在 盐酸 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 为溶剂， 反应 0.5h， 生成 N6-(3-(3,4-dichlorophenoxy)propyl)-2-phenyl-1,2-dihydro-1,3,5-triazine-4,6-diamine hydrochloride
  参考文献：
  名称：

  Expeditious synthesis and biological evaluation of novel 2,N6-disubstituted 1,2-dihydro-1,3,5-triazine-4,6-diamines as potential antimalarials

  摘要：

  A small set of novel 2,N-6-disubstituted 1,2-dihydro-1,3,5-triazine-4,6-diamines was prepared possessing a flexible tether between the exocyclic nitrogen bonded to C-6 of the 1,2-dihydro-1,3,5-triazine-4,6-diamine heterocycle and the distal aryl ring. Three zones were varied in this series of compounds, namely the nature of the substituent(s) on C-2; the nature of the substituent(s) on the distal aryl ring; as well as the nature and length of the flexible tether between the rings. The compound showing the best antimalarial activity (cycloguanil-resistant FCR-3 Plasmodium falciparum IC50 = 0.99 mu M) was N-6-(3-(4-chlorophenoxy)propyl)-2-(furan-2-yl)-1,2-dihydro-1,3,5-triazine-4,6-diamine hydrochloride. (C) 2011 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2011.02.054
• 作为产物：
  描述：

  3,4-二氯苯酚 在 caesium carbonate 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 73.0h， 生成 3-(3,4-dichlorophenoxy)propan-1-amine
  参考文献：
  名称：

  [EN] PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS
  [FR] COMPOSÉS DE PYRROLINONE-CARBOXAMIDE UTILES EN TANT QU'INHIBITEURS DE LIPASE ENDOTHÉLIALE

  摘要：

  本发明提供了Formula (I)或Formula (III)的化合物：[在此插入化学结构] (I) [在此插入化学结构] (III)，如规范中定义的，并包括任何这类新化合物的组合物。这些化合物是内皮脂酶抑制剂，可用作药物。

  公开号：

  WO2013048982A1

文献信息

• [EN] PYRIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE<br/>[FR] INHIBITEURS PYRIDINEDIONE CARBOXAMIDE DE LIPASE ENDOTHÉLIALE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2013048930A1

  公开（公告）日：2013-04-04

  The present invention provides compounds of Formula (I) as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments.

  本发明提供了如规范中定义的化合物(I)的化合物和包含任何此类新化合物的组合物。这些化合物是内皮脂酶抑制剂，可用作药物。
• Discovery of dihydropyrazino-benzimidazole derivatives as metabotropic glutamate receptor-2 (mGluR2) positive allosteric modulators (PAMs)
  作者：György Szabó、Sándor Kolok、Zoltán Orgován、Mónika Vastag、Zoltán Béni、János Kóti、Katalin Sághy、György I. Lévay、István Greiner、György M. Keserű

  DOI：10.1016/j.ejmech.2019.111881

  日期：2020.1

  A scaffold hopping strategy converted the known 1-[(1-methyl-1H-imidazol-2-yl)methyl]-4-phenylpiperidine core (1 and 2) by cyclization to a fused [6 + 5+6] membered heterocyclic mGluR2 PAM scaffold. Pharmacophore guided structure-activity relationship (SAR) studies resulted in a series of potent and metabolically stable mGluR2 PAMs. A representative optimized compound (95) having the most balanced

  支架跳跃策略通过环化将已知的[[1-（1-甲基-1H-咪唑-2-基）甲基] -4-苯基哌啶核心（1和2）转化为稠合的[6 + 5 + 6]杂环mGluR2 PAM脚手架。药理学指导的结构活性关系（SAR）研究导致了一系列有效且代谢稳定的mGluR2 PAM。具有最平衡特征的代表性优化化合物（95）在PCP诱导的小鼠超运动模型中显示了功效，该模型揭示了新的化学型是靶向mGluR2受体的有希望的PAM导联，并为进一步的翻译研究提供了支持。
• Design, synthesis and biological evaluation of 6-aryl-1,6-dihydro-1,3,5-triazine-2,4-diamines as antiplasmodial antifolates
  作者：Anna C. U. Lourens、David Gravestock、Robyn L. van Zyl、Heinrich C. Hoppe、Natasha Kolesnikova、Supannee Taweechai、Yongyuth Yuthavong、Sumalee Kamchonwongpaisan、Amanda L. Rousseau

  DOI：10.1039/c6ob01350c

  日期：——

  biological evaluation of a series of 6-aryl-1,6-dihydro-1,3,5-triazine-2,4-diamines is described. These compounds exhibited in vitro antiplasmodial activity in the low nanomolar range against both drug sensitive and drug resistant strains of P. falciparum, with 1-(3-(2,4-dichlorophenoxy)propyl)-6-phenyl-1,6-dihydro-1,3,5-triazine-2,4-diamine hydrochloride identified as the most potent compound from this series

  描述了一系列6-芳基-1,6-二氢-1,3,5-三嗪-2,4-二胺的设计，合成和生物学评估。这些化合物具有1-（3-（2,4-二氯苯氧基）丙基）-6-苯基-1,6-二氢的低纳摩尔浓度范围对恶性疟原虫的药物敏感菌株和耐药菌株均具有体外抗疟原虫活性。-1,3,5-三嗪-2,4-二胺盐酸盐被确定为该系列抗药性FCR-3菌株（IC 50 2.66 nM）最有效的化合物。该化合物在治疗浓度下对哺乳动物细胞无毒，在生化酶测定中显示为寄生DHFR抑制剂。
• Protein tyrosine phosphatase inhibitors and methods of use thereof
  申请人：Blaskovich Arnold Thomas Mark

  公开号：US20060142250A1

  公开（公告）日：2006-06-29

  The present invention provides compounds of Formula (I) and Formula (II) that are useful for modulating the biological activity of the protein tyrosine phosphatase-1b (PTP1B) enzyme. Compounds of this invention can be used to treat diseases and/or conditions in which the PTP1B enzyme is a factor. Such diseases and/or conditions include, but are not limited to, Type 1 diabetes, Type 2 diabetes, inadequate glucose tolerance, insulin resistance, obesity, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL levels, atherosclerosis, vascular restenosis, inflammatory bowel disease, pancreatitis, adipose cell tumors, adipose cell carcinoma, liposarcoma, dyslipidemia, cancer, and neurodegenerative diseases.

  本发明提供了式（I）和式（II）的化合物，这些化合物对于调节蛋白酪氨酸磷酸酶-1b（PTP1B）酶的生物活性是有用的。本发明的化合物可用于治疗PTP1B酶是因素的疾病和/或病况。这些疾病和/或病况包括但不限于1型糖尿病、2型糖尿病、葡萄糖耐量不足、胰岛素抵抗、肥胖症、高脂血症、高三酰甘油血症、高胆固醇血症、低高密度脂蛋白水平、动脉粥样硬化、血管再狭窄、炎症性肠病、胰腺炎、脂肪细胞肿瘤、脂肪细胞癌、脂肪肉瘤、脂质代谢异常、癌症和神经退行性疾病。
• PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF
  申请人：Blaskovich Mark Arnold Thomas

  公开号：US20090131374A1

  公开（公告）日：2009-05-21

  The present invention provides compounds of Formula (I) and Formula (II) that are useful for modulating the biological activity of the protein tyrosine phosphatase-1b (PTP1B) enzyme. Compounds of this invention can be used to treat diseases and/or conditions in which the PTP1B enzyme is a factor. Such diseases and/or conditions include, but are not limited to, Type 1 diabetes, Type 2 diabetes, inadequate glucose tolerance, insulin resistance, obesity, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL levels, atherosclerosis, vascular restenosis, inflammatory bowel disease, pancreatitis, adipose cell tumors, adipose cell carcinoma, liposarcoma, dyslipidemia, cancer, and neurodegenerative diseases.

  本发明提供了公式（I）和公式（II）的化合物，这些化合物对于调节蛋白酪氨酸磷酸酶-1b（PTP1B）酶的生物活性是有用的。本发明的化合物可用于治疗PTP1B酶是因素的疾病和/或病况。这些疾病和/或病况包括但不限于1型糖尿病，2型糖尿病，不足的葡萄糖耐受性，胰岛素抵抗，肥胖症，高脂血症，高三酰甘油血症，高胆固醇血症，低高密度脂蛋白水平，动脉粥样硬化，血管再狭窄，炎症性肠病，胰腺炎，脂肪细胞肿瘤，脂肪细胞癌，脂肪肉瘤，脂质代谢异常，癌症和神经退行性疾病。